3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Neoplasms
3
Prostatic Neoplasms
2
Pain, Postoperative
2
Pain
2
Neuroma
2
Chronic Pain
2
Breast Diseases
2
Wounds and Injuries
1
Stroke
1
Stomach Neoplasms
1
Spinal Cord Injuries
1
Skin Diseases
1
Rectal Neoplasms
1
Prostatic Hyperplasia
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Muscular Atrophy
1
Muscle Spasticity
1
Lower Urinary Tract Symptoms
1
Low Anterior Resection Syndrome
1
Head and Neck Neoplasms
1
Gastroparesis
1
Ganglion Cysts
1
Esophageal Neoplasms
1
Esophageal Motility Disorders
1
Esophageal Diseases
1
Esophageal Achalasia
1
Cluster Headache
1
Brain Injuries
1
Interventions
padeliporfin
5
Nivolumab
3
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Radiosurgery
2
Cyclophosphamide
2
Cisplatin
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
spartalizumab
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
guadecitabine
1
genexol-PM
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Site
×
Botulinum Toxins, Type A
×
Clear all
NCT01427400
2016-07-29
Botox
University of British Columbia
Phase 4
Unknown
128 enrolled